1 week Ago By ABMN Staff
Wellington Management Group LLP cut its holdings in Viridian Therapeutics, Inc. ( NASDAQ:VRDN – Free Report ) by 4.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor owned 224,484 shares of the company’s stock after selling 11,503 shares during the period. Wellington Management Group LLP owned 0.28% of Viridian Therapeutics worth $4,303,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. R Squared Ltd purchased a new position in shares of Viridian Therapeutics in the fourth quarter worth $26,000. AlphaQuest LLC increased its holdings in Viridian Therapeutics by 119.
0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after acquiring an additional 1,519 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Viridian Therapeutics during the 4th quarter valued at about $164,000.
KLP Kapitalforvaltning AS purchased a new position in shares of Viridian Therapeutics during the fourth quarter valued at about $219,000. Finally, E Fund Management Co. Ltd.
bought a new stake in shares of Viridian Therapeutics in the fourth quarter worth about $235,000. Wall Street Analysts Forecast Growth A number of equities analysts recently commented on VRDN shares. HC Wainwright reissued a “buy” rating and set a $34.
00 price target on shares of Viridian Therapeutics in a research note on Monday, December 16th. Wells Fargo & Company restated an “equal weight” rating and issued a $27.00 price target (down previously from $37.
00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Royal Bank of Canada increased their price objective on shares of Viridian Therapeutics from $44.00 to $47.
00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. Finally, Needham & Company LLC restated a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th.
Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Viridian Therapeutics has an average rating of “Moderate Buy” and an average target price of $35.
70. Viridian Therapeutics Stock Up 5.3 % Shares of NASDAQ VRDN opened at $12.
02 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.
55 and a quick ratio of 18.55. The firm has a 50-day simple moving average of $15.
08 and a two-hundred day simple moving average of $18.94. Viridian Therapeutics, Inc.
has a 1 year low of $9.90 and a 1 year high of $27.20.
The company has a market cap of $979.45 million, a P/E ratio of -2.79 and a beta of 0.
81. Viridian Therapeutics ( NASDAQ:VRDN – Get Free Report ) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.
81) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.24.
Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%.
The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million.
Research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.
About Viridian Therapeutics ( Free Report ) Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. Read More Want to see what other hedge funds are holding VRDN? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Viridian Therapeutics, Inc. ( NASDAQ:VRDN – Free Report ). Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
